<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746811</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-08007</org_study_id>
    <nct_id>NCT00746811</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Two-period Crossover Trial to Assess the Effects of 4 g/d P-OM3 on LDL-C and Other Aspects of the Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provident Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Provident Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the effects of 4 g/d P-OM3, compared with placebo,
      on LDL-C and other aspects of the fasting lipid profile in subjects with primary
      hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 2
      (Week 0), subjects meeting all entry criteria will be randomized to one of two treatment
      sequences: placebo or P-OM3 for the first 6 week phase followed by the study product they did
      not receive during the first phase (P-OM3 or placebo) for the second 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome variable will be the percent change from baseline in LDL-C during each treatment.</measure>
    <time_frame>Baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in other lipid and biomarker levels</measure>
    <time_frame>Baseline through end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>P-OM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo for the first six weeks of treatment. P-OM3 for the second six weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P-OM3</intervention_name>
    <description>4 grams/day - 4 one gram capsules</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 grams/day - 4 one gram capsules</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ages 18-79 inclusive

          -  Fasting, untreated low-density lipoprotein cholesterol (LDL-C)level in the borderline
             high to very high range

          -  Fasting, untreated triglyceride (TG)level in the normal range

          -  Provide written informed consent and authorization for protected health information

        Exclusion Criteria:

          -  CHD or CHD risk equivalent

          -  Pregnancy

          -  Use of lipid altering medications which cannot be stopped

          -  Body mass index over 45 kg per square meter

          -  Allergy or sensitivity to omega-3 fatty acids

          -  Certain muscle, liver, kidney, lung or gastrointestinal conditions

          -  Poorly controlled hypertension

          -  Certain medications

          -  Active cancers treated within prior 2 years (except non-melanoma skin cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin C. Maki, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Provident Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Provident Clinical Research</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Marshall, RN, BSN</last_name>
      <phone>630-617-2000</phone>
      <email>research@providentcrc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kevin C. Maki, PhD, Chief Science Officer</name_title>
    <organization>Provident Clinical Research</organization>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>omega 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 16, 2017</submitted>
    <returned>November 17, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

